150 related articles for article (PubMed ID: 32731189)
1. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
[TBL] [Abstract][Full Text] [Related]
4. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
5. Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Sender S; Sekora A; Villa Perez S; Chabanovska O; Becker A; Ngezahayo A; Junghanss C; Murua Escobar H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435587
[TBL] [Abstract][Full Text] [Related]
6. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
[TBL] [Abstract][Full Text] [Related]
7. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
8. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
10. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
[TBL] [Abstract][Full Text] [Related]
11. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
12. 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase.
Krajčovičová S; Jorda R; Vanda D; Soural M; Kryštof V
Eur J Med Chem; 2021 Feb; 211():113094. PubMed ID: 33340912
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
14. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Babu Boga S; Alhassan AB; Yu W; Selyutin O; Yu Y; Anand R; Xu J; Kelly J; Duffy JL; Liu S; Yang C; Wu H; Cai J; Bennett C; Maloney KM; Tyagarajan S; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA
Bioorg Med Chem Lett; 2020 Sep; 30(17):127390. PubMed ID: 32738973
[TBL] [Abstract][Full Text] [Related]
15. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
Craxton A; Jiang A; Kurosaki T; Clark EA
J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
[TBL] [Abstract][Full Text] [Related]
16. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
17. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract][Full Text] [Related]
18. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
Su R; Diao Y; Sha W; Dou D; Yu Z; Leng L; Zhao Z; Chen Z; Li H; Xu Y
Bioorg Chem; 2022 Sep; 126():105860. PubMed ID: 35661525
[TBL] [Abstract][Full Text] [Related]
20. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
Series J; Ribes A; Garcia C; Souleyreau P; Bauters A; Morschhauser F; Jürgensmeier JM; Sié P; Ysebaert L; Payrastre B
J Thromb Haemost; 2020 Dec; 18(12):3336-3351. PubMed ID: 32926549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
